新型口服头孢菌素S-1090的体外和体内抗菌活性
In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
作者信息
Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K
机构信息
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
出版信息
Antimicrob Agents Chemother. 1995 Nov;39(11):2544-51. doi: 10.1128/AAC.39.11.2544.
Abstract
S-1090, a new oral cephalosporin, was active against selected gram-negative bacteria and methicillin-susceptible clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus warneri, against which it had excellent activity. S-1090 was the most active compound against Streptococcus pyogenes and Streptococcus agalactiae among the agents compared. The in vivo efficacy of S-1090 against systemic and urinary and respiratory tract infections caused by gram-positive and -negative bacteria was superior to that expected from the in vitro and in vivo activities of the agents against which it was compared.
摘要
新型口服头孢菌素S - 1090对特定革兰氏阴性菌以及金黄色葡萄球菌、表皮葡萄球菌和沃氏葡萄球菌的甲氧西林敏感临床分离株具有活性，对这些菌株它表现出优异的活性。在被比较的药物中，S - 1090是对化脓性链球菌和无乳链球菌活性最强的化合物。S - 1090针对革兰氏阳性和阴性细菌引起的全身感染、泌尿系统感染及呼吸道感染的体内疗效优于根据与其比较的药物的体外和体内活性所预期的疗效。
相似文献
1
In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
Antimicrob Agents Chemother. 1995 Nov;39(11):2544-51. doi: 10.1128/AAC.39.11.2544.
2
In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin.
Antimicrob Agents Chemother. 1993 Jan;37(1):60-6. doi: 10.1128/AAC.37.1.60.
3
In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
Antimicrob Agents Chemother. 2003 Aug;47(8):2507-12. doi: 10.1128/AAC.47.8.2507-2512.2003.
4
In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Antimicrob Agents Chemother. 2003 Dec;47(12):3750-9. doi: 10.1128/AAC.47.12.3750-3759.2003.
5
In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Chemotherapy. 1994 May-Jun;40(3):167-82. doi: 10.1159/000239189.
6
Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.
Antimicrob Agents Chemother. 1993 Jan;37(1):100-5. doi: 10.1128/AAC.37.1.100.
7
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Jpn J Antibiot. 2002 Dec;55(6):800-7.
8
In vitro and in vivo activities of LB10522, a new catecholic cephalosporin.
Antimicrob Agents Chemother. 1996 Aug;40(8):1825-31. doi: 10.1128/AAC.40.8.1825.
9
[Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field].
Jpn J Antibiot. 1993 Jul;46(7):604-28.
10
In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum.
J Antimicrob Chemother. 1996 Apr;37(4):711-26. doi: 10.1093/jac/37.4.711.
引用本文的文献
1
The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.
Front Microbiol. 2022 Mar 24;13:807955. doi: 10.3389/fmicb.2022.807955. eCollection 2022.
2
Improved selective isolation of Bordetella pertussis by use of modified cyclodextrin solid medium.
J Clin Microbiol. 2009 Dec;47(12):4164-7. doi: 10.1128/JCM.00176-09. Epub 2009 Oct 21.
3
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.
Drugs. 2007;67(16):2355-82. doi: 10.2165/00003495-200767160-00005.
4
Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
Drugs. 2004;64(13):1433-64. doi: 10.2165/00003495-200464130-00004.
5
In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems.
Antimicrob Agents Chemother. 1999 Mar;43(3):460-4. doi: 10.1128/AAC.43.3.460.
6
State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.
Infection. 1998 Jul-Aug;26(4):242-6. doi: 10.1007/BF02962373.
7
In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
Antimicrob Agents Chemother. 1998 Jan;42(1):94-9. doi: 10.1128/AAC.42.1.94.
本文引用的文献
1
Carnitine status and safety after administration of S-1108, a new oral cephem, to patients.
Antimicrob Agents Chemother. 1993 May;37(5):1043-9. doi: 10.1128/AAC.37.5.1043.
2
Update on clinical significance of coagulase-negative staphylococci.
Clin Microbiol Rev. 1994 Jan;7(1):117-40. doi: 10.1128/CMR.7.1.117.
3
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.
Antimicrob Agents Chemother. 1984 Jan;25(1):98-104. doi: 10.1128/AAC.25.1.98.
4
Pivampicillin-promoted excretion of pivaloylcarnitine in humans.
Biochem Pharmacol. 1987 Oct 15;36(20):3405-9. doi: 10.1016/0006-2952(87)90318-2.
5
In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.
Antimicrob Agents Chemother. 1987 Jul;31(7):1085-92. doi: 10.1128/AAC.31.7.1085.
6
Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.
J Antibiot (Tokyo). 1989 Jun;42(6):977-88. doi: 10.7164/antibiotics.42.977.
7
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
Antimicrob Agents Chemother. 1989 Oct;33(10):1795-800. doi: 10.1128/AAC.33.10.1795.
8
In vitro antibacterial activity of ME1207, a new oral cephalosporin.
Antimicrob Agents Chemother. 1991 Aug;35(8):1691-4. doi: 10.1128/AAC.35.8.1691.
9
Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans.
Antimicrob Agents Chemother. 1992 Apr;36(4):757-61. doi: 10.1128/AAC.36.4.757.
Zotero 插件